36 results on '"Hahn, Andrew W"'
Search Results
2. Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC).
3. Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials.
4. Genomic alterations associated with the progression from castration-sensitive to castration-resistant metastatic prostate cancer based on machine learning analysis of cell-free DNA genomic profile.
5. Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints.
6. Association of serum iron and response to immune checkpoint inhibitors (ICIs) in metastatic clear cell renal cell carcinoma (mccRCC).
7. Genomic alterations in visceral versus nonvisceral “metastatic” site tumor tissue in metastatic prostate cancer (mPC).
8. Identification of genomic aberrations associated with overall survival in metastatic clear cell renal cell carcinoma (mccRCC).
9. Response to systemic therapy and survival outcomes in de-novo (D1) metastatic castration-sensitive prostate cancer (mCSPC) versus mCSPC with prior local therapy (D0).
10. Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival outcome in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC).
11. Immune correlates of CD73 expression in patients with urothelial carcinoma (UC).
12. Genomic landscape of metastatic hormone sensitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA).
13. Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients.
14. Efficacy of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients (pts) with refractory metastatic renal cell carcinoma (mRCC).
15. A Genome-wide association study of metastatic prostate cancer.
16. Receipt of systemic therapy in older versus younger patients (pts) with metastatic renal cell carcinoma (mRCC).
17. Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
18. Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.
19. Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
20. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC) over treatment and time.
21. Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.
22. Germline variant alleles in rs12422149 of SLCO2B1 and response to abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
23. Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment
24. Germline variant in HSD3B1 (1245 A>C) and response to abiraterone acetate plus prednisone (AA) in men with new onset metastatic castration-resistant prostate cancer (mCRPC).
25. Independent assessment of TP53 and PTEN as predictors of response to enzalutamide (ENZ) or abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
26. Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
27. Association of somatic mutational burden with depression and anxiety in patients with metastatic urothelial cancer (mUC).
28. Targeting bacteroides in the stool microbiome and response to treatment (Rx) with first-line VEGFTKI in metastatic renal cell carcinoma (mRCC).
29. Current Treatment Landscape of Advanced Papillary Renal Cancer
30. Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
31. Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC).
32. Intra-individual genomic diversity between circulating tumor cell-free DNA (cfDNA) and tumor tissue testing in metastatic renal cell carcinoma (mRCC).
33. Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer.
34. Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC).
35. Independent validation of effect of HSD3B1 genotype on response to androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer (HSPC).
36. Efficacy of eplerenone (Epe) in the management of mineralocorticoid excess (MCE) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (AA) without prednisone (P).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.